Immunogenicity of peptide-based vaccine composed of epitopes from Echinococcus granulosus rEg.P29.
E. granulosus
Th1 cells
antibody
immune memory
immunogenicity
peptide vaccine
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
29
12
2022
received:
09
10
2022
accepted:
30
01
2023
entrez:
27
2
2023
pubmed:
28
2
2023
medline:
3
3
2023
Statut:
ppublish
Résumé
Echinococcus granulosus is one of the main causes of economic loss in the livestock industry because of its food-borne transmission. Cutting off the transmission route is a valid prevention method, and vaccines are the most effective means of controlling and eliminating infectious diseases. However, no human-related vaccine has been yet marketed. As a genetic engineering vaccine, recombinant protein P29 of E. granulosus (rEg.P29) could provide protection against deadly challenges. In this study, we generated peptide vaccines (rEg.P29
Identifiants
pubmed: 36848174
doi: 10.1096/fj.202201636R
doi:
Substances chimiques
Vaccines, Subunit
0
Blood Group Antigens
0
Epitopes
0
Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e22819Informations de copyright
© 2023 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
Références
Lightowlers MW, Gasser RB, Hemphill A, et al. Advances in the treatment, diagnosis, control and scientific understanding of taeniid cestode parasite infections over the past 50 years. Int J Parasitol. 2021;51:1167-1192.
Woolsey ID, Miller AL. Echinococcus granulosus sensu lato and Echinococcus multilocularis: a review. Res Vet Sci. 2021;135:517-522.
Tamarozzi F, Deplazes P, Casulli A. Reinventing the wheel of Echinococcus granulosus sensu lato transmission to humans. Trends Parasitol. 2020;36:427-434.
Sander VA, Sanchez LE, Mendoza ML, Ramos DV, Corigliano MG, Clemente M. Use of veterinary vaccines for livestock as a strategy to control foodborne parasitic diseases. Front Cell Infect Microbiol. 2020;10:288.
Wang H, Li Z, Gao F, et al. Immunoprotection of recombinant Eg.P29 against Echinococcus granulosus in sheep. Vet Res Commun. 2016;40:73-79.
Oscherwitz J. The promise and challenge of epitope-focused vaccines. Hum Vaccin Immunother. 2016;12:2113-2116.
Malonis RJ, Lai JR, Vergnolle O. Peptide-based vaccines: current Progress and future challenges. Chem Rev. 2020;120:3210-3229.
Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide vaccine: progress and challenges. Vaccines (Basel). 2014;2:515-536.
Kumai T, Yamaki H, Kono M, Hayashi R, Wakisaka R, Komatsuda H. Antitumor peptide-based vaccine in the limelight. Vaccines (Basel). 2022;10:70.
Vassilakopoulou V, Karachaliou CE, Evangelou A, Zikos C, Livaniou E. Peptide-based vaccines for neurodegenerative diseases: recent endeavors and future perspectives. Vaccines (Basel). 2021;9:1278.
Momtazi-Borojeni AA, Pirro M, Xu S, Sahebkar A. PCSK9 inhibition-based therapeutic approaches: an immunotherapy perspective. Curr Med Chem. 2022;29:980-999.
Charneau J, Suzuki T, Shimomura M, Fujinami N, Nakatsura T. Peptide-based vaccines for hepatocellular carcinoma: a review of recent advances. J Hepatocell Carcinoma. 2021;8:1035-1054.
Forner M, Canas-Arranz R, Defaus S, et al. Peptide-based vaccines: foot-and-mouth disease virus, a paradigm in animal health. Vaccines (Basel). 2021;9:477.
Swaminathan A, Lucas RM, Dear K, McMichael AJ. Keyhole limpet haemocyanin-a model antigen for human immunotoxicological studies. Br J Clin Pharmacol. 2014;78:1135-1142.
Kahn RM, Ragupathi G, Zhou QC, et al. Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination. Cancer Immunol Immunother. 2023;72(1):183-191.
Hung JT, Chen IJ, Ueng SH, et al. The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer. J Immunother Cancer. 2022;10:e004312.
Saghari M, Gal P, Gilbert S, et al. OX40L inhibition suppresses KLH-driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof-of-pharmacology for KY1005. Clin Pharmacol Ther. 2022;111:1121-1132.
O'Cearbhaill RE, Deng W, Chen LM, et al. A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: an NRG oncology/GOG study. Gynecol Oncol. 2019;155(3):393-399.
Olive C, Batzloff MR, Toth I. Lipid core peptide technology and group a streptococcal vaccine delivery. Expert Rev Vaccines. 2004;3(1):43-58.
Lv Y, Li S, Zhang T, et al. Identification of B-cell dominant epitopes in the recombinant protein P29 from Echinococcus granulosus. Immun Inflamm Dis. 2022;10:e611.
Lv Y, Zhu Y, Chang L, et al. Identification of a dominant murine T-cell epitope in recombinant protein P29 from Echinococcus granulosus. Acta Biochim Biophys Sin (Shanghai). 2022;54:1-12.
Du X, Zhu M, Zhang T, et al. The recombinant Eg.P29-mediated miR-126a-5p promotes the differentiation of mouse naive CD4(+) T cells via DLK1-mediated Notch1 signal pathway. Front Immunol. 2022;13:773276.
Li M, Zhu Y, Niu C, et al. Design of a multi-epitope vaccine candidate against Brucella melitensis. Sci Rep. 2022;12:10146.
Tan C, Zhu F, Xiao Y, et al. Immunoinformatics approach toward the introduction of a novel multi-epitope vaccine against Clostridium difficile. Front Immunol. 2022;13:887061.
Gauci C, Heath D, Chow C, Lightowlers MW. Hydatid disease: vaccinology and development of the EG95 recombinant vaccine. Expert Rev Vaccines. 2005;4:103-112.
Heath DD, Koolaard J. Serological monitoring of protection of sheep against Echinococcus granulosus induced by the EG95 vaccine. Parasite Immunol. 2012;34:40-44.
Valizadeh M, Haghpanah B, Badirzadeh A, Roointan E, Fallahi S, Raeghi S. Immunization of sheep against Echinococcus granulosus with protoscolex tegumental surface antigens. Vet World. 2017;10(8):854-858.
Gottstein B, Soboslay P, Ortona E, Wang J, Siracusano A, Vuitton D. Immunology of alveolar and cystic echinococcosis (AE and CE). Adv Parasitol. 2017;96:1-54.
Yasen A, Li W, Aini A, et al. Th1/Th2/Th17 cytokine profile in hepatic cystic echinococcosis patients with different cyst stages. Parasite Immunol. 2021;43:e12839.
Ortona E, Rigano R, Buttari B, et al. An update on immunodiagnosis of cystic echinococcosis. Acta Trop. 2003;85:165-171.
Valeri M, Raffatellu M. Cytokines IL-17 and IL-22 in the host response to infection. Pathog Dis. 2016;74:ftw111.
Amezcua VM, Rodriguez C, Gruppi A, Acosta RE. Interleukin-17 mediated immunity during infections with Trypanosoma cruzi and other protozoans. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165706.
Sette A, Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Immunol Rev. 2022;310(1):27-46.